Cholestenone-13C

Modify Date: 2024-01-22 21:44:38

Cholestenone-13C structure	Common Name	Cholestenone-13C
	CAS Number	68165-57-1	Molecular Weight	385.63
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₆₁₃CH₄₄O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Cholestenone-13C

Cholestenone-13C is the 13C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells[1][2][3].

Name	4-cholesten-3-one-4-13c
Synonym	More Synonyms

Description	Cholestenone-13C is the 13C labeled Cholestenone. Cholestenone (4-Cholesten-3-one), the intermediate oxidation product of cholesterol, is metabolized primarily in the liver. Cholestenone is highly mobile in membranes and influences cholesterol flip-flop and efflux. Cholestenone may cause long-term functional defects in cells[1][2][3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Rosenheim O, et al. The mechanism of coprosterol formation in vivo: 1. Cholestenone as an intermediate. Biochem J. 1943 Oct;37(4):513-4. [3]. Neuvonen M, et, al. Enzymatic oxidation of cholesterol: properties and functional effects of cholestenone in cell membranes. PLoS One. 2014 Aug 26;9(8):e103743.

Description

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Rosenheim O, et al. The mechanism of coprosterol formation in vivo: 1. Cholestenone as an intermediate. Biochem J. 1943 Oct;37(4):513-4.

[3]. Neuvonen M, et, al. Enzymatic oxidation of cholesterol: properties and functional effects of cholestenone in cell membranes. PLoS One. 2014 Aug 26;9(8):e103743.